BridgeBio Pharma Company Leadership

BridgeBio Pharma's latest congressional trading

BridgeBio Pharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.4348) % which means that it has lost $0.4348 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.8967) %, meaning that it created substantial loss on money invested by shareholders. BridgeBio Pharma's management efficiency ratios could be used to measure how well BridgeBio Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of January 2026, Return On Equity is likely to grow to 0.34, while Return On Tangible Assets are likely to drop (0.72). At this time, BridgeBio Pharma's Non Current Assets Total are very stable compared to the past year. As of the 26th of January 2026, Other Assets is likely to grow to about 170 M, while Total Assets are likely to drop about 687.5 M. As of the 26th of January 2026, Common Stock Shares Outstanding is likely to drop to about 144.2 M. In addition to that, Net Loss is likely to drop to about (454.7 M)The majority of BridgeBio Pharma outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in BridgeBio Pharma to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in BridgeBio Pharma. Please pay attention to any change in the institutional holdings of BridgeBio Pharma as this could imply that something significant has changed or is about to change at the company. On September 12, 2025, Representative Gilbert Cisneros of US Congress acquired under $15k worth of BridgeBio Pharma's common stock. Some institutional investors establish a significant position in stocks such as BridgeBio Pharma in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of BridgeBio Pharma, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

BridgeBio Pharma Workforce Comparison

BridgeBio Pharma Profit Margins

The company has Profit Margin (PM) of (2.25) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.13) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.13.

BridgeBio Pharma Insider Trading History

BridgeBio Pharma Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as BridgeBio Pharma often depends on how effective the management is. BridgeBio Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BridgeBio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BridgeBio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.